News

/
/
WP5-SA6 Joint “Rapid relative effectiveness assessment of new pharmaceuticals for the treatment of chronic Hepatitis C” is now available

WP5-SA6 Joint “Rapid relative effectiveness assessment of new pharmaceuticals for the treatment of chronic Hepatitis C” is now available

We are pleased to announce that the Joint “Rapid relative effectiveness assessment of new pharmaceuticals for the treatment of chronic Hepatitis C” og WP5-SA6 is now available.
This joint rapid assessment of WP5 Strand A evaluates multiple new pharmaceuticals for the treatment of Chronic Hepatitis C.

Find the joint assessment here.

This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.